Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016
November 03 2016 - 2:30AM
Neovacs (Alternext Paris:ALNEV) a leader in active
immunotherapy for the treatment of autoimmune diseases, today
announced its participation at the Jefferies 2016 London Healthcare
Conference taking place November 16-17 at the Waldorf Hilton in
London, UK.
This Conference is the largest healthcare meeting in Europe
dedicated to companies from around the world from the
biotechnology, pharmaceutical, generic, consumer health, medical
technology and Healthcare Service sectors. Last year, the Jefferies
conference hosted over 300 participating companies, 1,200 attendees
and 3,700 business-to-business and investor meetings.
The two-day event will include concurrent tracks of company
presentations, thematic panel discussions, and 1x1/small-group
meetings. This global gathering of leading healthcare executives
and institutional, private equity and venture capital investors
will address near- and long-term investment opportunities and
discuss the mechanisms driving global healthcare.
About Neovacs
Listed on Alternext Paris since 2010, Neovacs is
today a leading biotechnology company focused on an active
immunotherapy technology platform (Kinoids) with applications in
autoimmune and/or inflammatory diseases. On the basis of the
company’s proprietary technology for inducing a polyclonal immune
response (covered by five patent families that potentially run
until 2032) Neovacs is focusing its clinical development efforts on
IFNα-Kinoid, an immunotherapy being developed for the indication of
lupus, dermatomyositis and also in preclinical trial for Type 1
diabetes. Neovacs is also conducting preclinical development works
on other therapeutic vaccines in the fields of auto-immune
diseases, oncology and allergies. The goal of the Kinoid approach
is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
www.neovacs.fr
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Aug 2023 to Aug 2024